Nipocalimab is a fully human, anti-FcRn, aglycosylated IgG1 monoclonal antibody that reduces pathogenic alloantibodies in maternal circulation and blocks the placental transfer of maternal IgG to the ...

Please provide your email address to receive an email when new articles are posted on . Among pregnant women who received nipocalimab infusions, 54% had live births without an intrauterine transfusion ...

Please provide your email address to receive an email when new articles are posted on . Practice patterns vary widely for management of hemolytic disease of the fetus and newborn (HDFN). Researchers ...

When cancer subtypes were examined, the analysis revealed that phototherapy was linked to a 40% increased odds of blood cancers. More modest associations were observed for solid organ cancers and ...

Breakthrough Therapy Designation for nipocalimab based on results from the Phase 2 UNITY clinical trial for HDFN Phase 3 clinical trial enrollment underway, representing the only therapy reported to ...

Nipocalimab delayed or prevented severe fetal anemia and 54 percent of study participants in the Phase 2 UNITY study achieved a live birth at or after 32 weeks without the need for intrauterine ...

Johnson & Johnson drug nipocalimab is in late-stage clinical testing in a rare neuromuscular disorder, and if it stays on track could become the third-to-market drug in its class for that indication.

Mihir Raval, MD, MPH, comments on the difference between cold agglutinin disease and other autoimmune hemolytic anemias. Neil Minkoff, MD: Now, you had mentioned that there are other autoimmune ...